Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 5/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 9/20 | 0.52 |
| ▸ | PLK1 | P53350 | 9/20 | 0.52 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.52 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.52 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247616 | 1.00 | PTK2 (0.57) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4238562 | 0.97 | PTK2 (0.61) | PTK2AURKAAURKBRAD52BRD4 | |
| SCHEMBL4238559 | 0.97 | PTK2 (0.61) | PTK2AURKAAURKBRAD52BRD4 | |
| SCHEMBL4240061 | 0.95 | ALK (0.54) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4240056 | 0.95 | ALK (0.54) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4240072 | 0.93 | PTK2 (0.55) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4240068 | 0.93 | PTK2 (0.55) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4238706 | 0.93 | AURKA (0.57) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4238700 | 0.93 | AURKA (0.57) | PTK2AURKAAURKBLRRK2IGF1R | |
| SCHEMBL4238618 | 0.92 | PTK2 (0.48) | PTK2AURKAAURKBLRRK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100894-A1 | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |